Novel therapeutic agents for T-cell lymphomas.

Abstract

T-cell lymphomas are a heterogeneous group of T-cell malignancies arising from post-thymic mature T-cells. Together they account for 10-15% of all non-Hodgkin's lymphoma. Because of the different underlying pathology, different T-cell lymphoma subtypes may require different treatment approaches. In general, the treatment results of T-cell lymphomas, using conventional anthracycline-based combination chemotherapy, are disappointing. Though autologous or allogeneic stem cell transplantation may offer a cure to some of the patients, a substantial proportion of patients are not eligible for transplantation because of the chemo-refractoriness or short remission duration of the lymphomas. Novel therapies may open up the potential path for better disease control. We review several classes of novel treatment for T-cell lymphomas including monoclonal antibodies, epigenetic modifiers, newer generation of cytotoxics, and specific targeting agents that may improve treatment outcome.

• Authors: Thomas Sau-Yan Chan, Yok-Lam Kwong, Eric Tse
• Journal: Discovery medicine (Discov Med) Vol. 16 Issue 86 Pg. 27-35 (Aug 2013) ISSN: 1944-7930 [Electronic] United States
• PMID: 23911229 (Publication Type: Journal Article, Review)

Chemical References

• Antineoplastic Agents

Topics

• Antineoplastic Agents (administration & dosage)
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Humans
• Lymphoma, T-Cell (drug therapy, therapy)
• Prognosis
• Treatment Outcome